<DOC>
	<DOCNO>NCT00771251</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness golimumab patient active rheumatoid arthritis despite DMARD ( Disease-modifying antirheumatic drug ) therapy . Another objective evaluate pharmacokinetics golimumab .</brief_summary>
	<brief_title>A Safety Efficacy Study Golimumab ( CNTO148 ) Patients With Active Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description>This study design placebo-controlled study golimumab monotherapy purpose demonstrate safety effectiveness golimumab , new , fully human anti-TNF ( Tumor necrosis factor ) monoclonal antibody produce mean HuMab mouse technology . Other reason use study design follow : effect golimumab give alone must confirm case drug ; golimumab may use even patient treatment methotrexate ( MTX ) . There 3 treatment group study follow : CNTO148 50 mg group , CNTO 148 100 mg group , Placebo group .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients diagnose rheumatoid arthritis least 3 month prior registration definitely identify rheumatoid arthritis , time informed consent , accord criterion classification establish American College Rheumatology ( 1987 ) Patients previously respond least one DMARD ( informed consent obtain ) Patients , treatment DMARD , DMARD wash least 4 week first administration Patients least 6 swollen joint 6 tender joint time registration immediately first injection Patients history hypersensitivity human immunoglobulin proteins ingredient golimumab Patients previously experience suffer follow disease : ( ) Collagen disease rheumatoid arthritis , ( ii ) Latent active granulomatous infection histoplasmosis coccidioidomycosis , ( iii ) Felty syndrome , etc Patients severe , advanced , poorly control disease kidney , liver , blood , gastrointestinal system , endocrine system , lung , heart , nervous system , psychiatric system , brain</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Fully Human anti-TNFa monoclonal antibody</keyword>
	<keyword>CNTO148</keyword>
	<keyword>Golimumab</keyword>
</DOC>